← Product Code FRO · K070581 # SILVER ALGINATE II WOUND DRESSING (K070581) _Advanced Medical Solutions Limited · FRO · Jul 13, 2007 · SU · SESE_ **Canonical URL:** https://fda.innolitics.com/device/K070581 ## Device Facts - **Applicant:** Advanced Medical Solutions Limited - **Product Code:** FRO - **Decision Date:** Jul 13, 2007 - **Decision:** SESE - **Submission Type:** Traditional - **Device Class:** Class U - **Review Panel:** SU - **Attributes:** Therapeutic ## Intended Use Silver Alginate II Dressing is indicated for the management of moderate to heavily exuding partial to full thickness wounds, such as: - Post-operative wounds . - Trauma wounds (dermal lesions, trauma injuries or incisions) . - Leg Ulcers . - Pressures Ulcers . - Diabetic Ulcers ◆ - Graft and donor sites . - Post-operative surgical wounds . - 1st and 2nd degree burns . - Partial and Full Thickness wounds . Silver Alginate II Dressing is indicated for external use only ## Device Story Sterile, non-woven wound dressing composed of high G calcium alginate, carboxymethylcellulose (CMC), and ionic silver complex (Silver Sodium Hydrogen Zirconium Phosphate). Applied to wound surface; absorbs wound fluid to form gel, maintaining moist environment for healing and autolytic debridement. Ionic silver released in presence of wound fluid provides antimicrobial barrier against broad spectrum of microorganisms for up to 21 days. Odor reduction achieved via antibacterial effect. Used in clinical or home settings for wound management; applied by healthcare providers or patients. Facilitates intact removal of dressing. ## Clinical Evidence Bench testing only. Biocompatibility demonstrated per BS EN ISO 10993-1. Sterilization validation performed per harmonized standards. In-vitro testing supports antimicrobial efficacy and silver release profile for up to 21 days. ## Technological Characteristics Non-woven pad; materials: high G calcium alginate, carboxymethylcellulose (CMC), ionic silver complex (Silver Sodium Hydrogen Zirconium Phosphate). Biocompatibility: BS EN ISO 10993-1. Sterilization: validated per harmonized standards. Form factor: flat and rope dressings in various sizes. ## Predicate Devices - Silver Alginate II Dressing ([K041316](/device/K041316.md)) - Aquacel Ag ([K013814](/device/K013814.md)) - Acticoat ([K002896](/device/K002896.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ K070581 JUL 1 3 2007 ## Section 11 – Traditional 510(k): Device Modification -Summary This Traditional 510(k) Device Modification is to provide substantial equivalence for Advanced Medical Solutions Limited's Silver Alginate II Dressing, which is substantially equivalent to currently marketed devices intended for wound care. This product is already legally marketed as Silver Alginate II Dressing (unmodified device) and was previously cleared under 510(k) numbers K041316/K063173. Both submissions have been made by Advanced Medical Solutions Limited. | Submitted by: - | Advanced Medical Solutions Limited
Road Three
Winsford Industrial Estate
Winsford
Cheshire
CW7 3PD
United Kingdom | |---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Contact:- | Mrs Claire Ryan
Regulatory Affairs Manager | | Telephone: - | +44(0)1606 545569 | | Fax :- | +44(0)1606 863600 | | Email:- | Claire.ryan@admedsol.com | | Date prepared:- | 2nd February 2007 | | Classification :- | There is currently no classification for wound and burn
dressings. | | Common Name :- | Silver Alginate II Dressing | | Trade Names:- | Maxsorb Extra Ag
Seasorb Ag
Invacare Silver Alginate Dressing | | Predicate devices:- | K041316 Silver Alginate II Dressing manufactured by
Advanced Medical Solutions
K013814 Aquacel Ag with hydrofibre manufactured by
ConVatec, A division of E.R Squibb and Sons LLC.
K002896 Acticoat® manufactured by Smith & Nephew
Limited | {1}------------------------------------------------ Directions for use: -Silver Alginate II Dressing is indicated for the management of moderate to heavily exuding partial to full thickness wounds such as: - . Post-operative wounds - . Trauma wounds (dermal lesions, trauma injuries or incisions) - . Leg Ulcers - . Pressures Ulcers - Diabetic Ulcers ● - . Graft and donor sites - . Post-operative surgical wounds - 1st and 2nd degree burns ● - Partial and Full Thickness wounds . Silver Alginate II Dressing is indicated for external use only Device Description: -Silver Alginate II Dressing is a sterile, non woven pad composed of a high G (guluronic acid) calcium alginate, carboxymethylcellulose (CMC) and ionic silver complex (Silver Sodium Hydrogen Zirconium Phosphate), which releases silver ions in the presence of wound fluid. As wound fluid is absorbed the alginate forms a gel, which assists in maintaining a moist environment for optimal wound healing, and allows intact removal. > The silver ions protect the dressing from a broad spectrum of microorganisms over a period of up to twenty-one (21) days, based on in-vitro testing. . Odour reduction results from the antibacterial effect in the dressing. Silver Alginate II Dressing is an effective barrier to bacterial penetration. Silver Alginate II Dressing protects the wound and aids autolytic debridement therefore facilitating wound healing. {2}------------------------------------------------ | | The dressing has an off-white appearance and is available
in various sizes (5cm x 5cm, 10cm x 10cm, 15cm x 15cm,
10cm x 20cm, 20cm x 30cm flat dressings; 2.7cm x 30cm
and 3cm x 44cm flat rope dressings; and 30cm x 2g rope
dressings). The flat rope dressings are packaged in pouches
and the flat rope and rope dressings are packaged in a
blister pack. | |-----------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Testing:- | The biocompatibility of Advanced Medical Solutions
Limited Silver Alginate II Dressing has been demonstrated
to be in compliance with the requirements of BS EN ISO
10993-1. Sterilisation validation has been performed in
compliance with harmonised standards. | | Statement of: -
Substantial
Equivalence | The Silver Alginate II Dressing is a non-woven calcium
alginate dressing which is substantially equivalent in
construction and/or performance to both Anticoat® Calcium
Alginate Dressing and Aquacel Ag absorbent antimicrobial
wound dressing predicate devices. Comparable
absorbency, silver release profile and antimicrobial activity
have been demonstrated. | {3}------------------------------------------------ Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized symbol that resembles three abstract human figures or forms, arranged in a flowing, dynamic composition. Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 JUL 1 3 2007 Advanced Medical Solutions, Ltd % Ms. Claire Ryan Regulatory Affairs Manager Road Three, Winsford Industrial Estate Winsford, Cheshire, CW7 3PD United Kingdom Re: K070581 Trade/Device Name: Silver Alginate II Dressing Regulatory Class: Unclassified Product Code: FRO Dated: June 20, 2007 Received: June 22, 2007 Dear Ms. Ryan: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. {4}------------------------------------------------ Page 2 - Ms. Claire Ryan This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html. Sincerely yours, Mark N. Melkerson Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {5}------------------------------------------------ ## Indications for Use 510(k) Number (if known): K070581 Device Name: Silver Alginate II Dressing Indications for Use: Silver Alginate II Dressing is indicated for the management of moderate to heavily exuding partial to full thickness wounds, such as: - Post-operative wounds . - Trauma wounds (dermal lesions, trauma injuries or incisions) . - Leg Ulcers . - Pressures Ulcers . - Diabetic Ulcers ◆ - Graft and donor sites . - Post-operative surgical wounds . - 1st and 2nd degree burns . - Partial and Full Thickness wounds . Silver Alginate II Dressing is indicated for external use only Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use (21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evalua (Division & Division of General, Restorative, and Neurological Devices **510(k) Number** // $$020551$$ / --- **Source:** [https://fda.innolitics.com/device/K070581](https://fda.innolitics.com/device/K070581) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com